We have a large repository of ubiquitin ligases, assays developed to monitor their activities, affinity matrices to isolate poly-ubiquitin structures and ubiquitinated proteins that appear following mitophagy.
In addition, we have developed selective antibodies against ubiquitin and phospho-ubiquitin and other well-defined poly-ubiquitin structures. These tools are available to researchers under MTA agreements.
Academic and biopharmaceutical investigators can access our proprietary affinity matrices, ligase activity assays, and selective ubiquitin probes under standard MTA protocols to accelerate basic and translational research.
Ligase Repositories • pUB Antibodies • Affinity Matrices
Engineered matrices, validated assays, and selective antibodies for mitochondrial quality control research.
A comprehensive repository of ubiquitin ligases involved in cellular quality control, accompanied by robust biochemical assays developed specifically to monitor their enzymatic activities in mitophagy and mitobiogenesis.
Proprietary affinity matrices engineered to selectively capture and isolate poly-ubiquitin structures and ubiquitinated proteins that appear following mitochondrial damage and subsequent mitophagy.
High-affinity selective antibodies raised against ubiquitin, phospho-ubiquitin (pUB), and other well-defined poly-ubiquitin structures critical for detecting mitochondrial distress and neurodegenerative signatures.
The screening programs at Myto Health have discovered several inhibitors and activators of mitophagy from small molecules libraries and optimized medicinal chemistry approaches. We have also screened several natural product libraries to discover activators (nutraceuticals) that promote mitophagy and mitobiogenesis.
Mitophagy and mitobiogenesis are initiated by ubiquitin proteasome system (UPS). Myto Health has also established a diagnostic platform to monitor poly-ubiquitin signatures from human blood as biomarkers for diseases, with a focus on Parkinson’s disease.
Targeted screening against ubiquitin ligases has yielded small molecule activators that elevate mitophagy and enhance recovery from ischemic attack, along with GRAS-amenable natural compounds.
Myto Health has compiled a list of mutations in UPS enzymes that result in early and late onset PD. The structure of mutated enzyme and its relationship to function and pathology of PD has allowed Myto Health to establish an artificial intelligence platform which patients and providers can use to evaluate their predisposition to neurodegenerative diseases through inputting their genomic DNA sequence.
Myto Health’s overall platform allows discovery and development of drugs, nutraceuticals, and diagnostic tools to monitor susceptibility to neurodegeneration and help clinicians to select a patient population that responds to UPS mitochondrial targeting therapies.
